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Abstract
Common genetic variation at human 8q23.3 is significantly associated with colorectal cancer (CRC) risk. To elucidate the
basis of this association we compared the frequency of common variants at 8q23.3 in 1,964 CRC cases and 2,081 healthy
controls. Reporter gene studies showed that the single nucleotide polymorphism rs16888589 acts as an allele-specific
transcriptional repressor. Chromosome conformation capture (3C) analysis demonstrated that the genomic region
harboring rs16888589 interacts with the promoter of gene for eukaryotic translation initiation factor 3, subunit H (EIF3H).W e
show that increased expression of EIF3H gene increases CRC growth and invasiveness thereby providing a biological
mechanism for the 8q23.3 association. These data provide evidence for a functional basis for the non-coding risk variant
rs16888589 at 8q23.3 and provides novel insight into the etiological basis of CRC.
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Introduction
Although inherited susceptibility is responsible for ,30% of all
CRC [1], high-penetrance germline mutations in APC, the
mismatch repair (MMR) genes, MUTYH, SMAD4, BMPR1A
(ALK3) and STK11 account for ,6% of all CRC [2]. Recent
genome-wide association (GWA) studies we have conducted have
vindicated a polygenic model of susceptibility to CRC based on
the co-inheritance of multiple low-risk variants [3–9].
As the SNPs (or markers) genotyped during GWA studies are
generally not themselves strong candidates for causality, enumer-
ation of the genetic and functional basis at a specific locus poses a
significant challenge. However, as demonstrated by recent studies
of the 8q24 and 18q21 risk loci for CRC [10–12], dissecting the
genetic and functional basis of associations identified by GWA
studies can provide novel insights into cancer biology.
We have recently shown that common variation at 8q23 defined
by the SNP rs16892766 influences CRC risk [5,9,13]. To
elucidate a basis of this association we have systematically
interrogated the 8q23 association signal through targeted re-
sequencing, linkage disequilibrium (LD) mapping and functional
analyses.
He we show that a variant mapping to 8q23.3 may influence the
transcriptional regulation of eukaryotic translation initiation factor
3, subunit H (EIF3H), MIM 603912. These data provides strong
support for the functional significance of this SNP and may explain
the association observed for CRC at this locus.
Results
To investigate the 8q23 association and estimate the fraction of
common variation at this locus, we generated a fine scale map of a
300 Kb region encompassing the rs16892766 association signal
(117,650,000–117,950,000bps) using data from 154 SNPs directly
genotyped in 1,964 CRC cases and 2,081 controls and an
additional 112 SNPs imputed from HapMap (Dataset S1).
A 22 kb genomic region of linkage disequlibrium (LD;
Chr8:117,690,773–117,712,909; UCSC March 2006 assembly,
NCBI build36.1) capturing rs16892766 provided the best evidence
for the 8q23 CRC association signal (Figure 1). To annotate the
region we re-sequenced 90 CEU CEPH HapMap individuals (30
trios of U.S. residents of northern and western European ancestry
included in the HapMap Phase II project) as this cohort is
sufficient to capture all common variation (MAF.5%) [14]. Only
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owing to low-complexity genomic sequence. We identified 103
variants (Table S1); these included 97 SNPs and six insertion/
deletion polymorphisms. Of the 103 variants, 74 were common
(minor allele frequency [MAF] $0.05) but only 29 had been
genotyped by HapMap.
We calculated pair-wise LD statistics between each of the 74
common SNPs and rs16892766. Eight polymorphisms (7 SNPs, 1
insertion/deletion) showed evidence of high LD with rs16892766
(r
2$0.50; Figure S1 and Table S1). We genotyped these nine
polymorphismsinourseriesof 1,964CRCcasesand2,081 controls.
The strongest associations were provided by Novel SNP 28
(117,700,195 bp; P=4.55610
26), rs16892766 (P=1.13610
25),
rs16888589 (P=8.42610
26) and rs11986063 (P=5.49610
26),
(Figure 1; Table S2). To explore the possibility that we may have
failed to identify a potential candidate variant we re-examined the
association and using data generated from sequencing the 90 CEU
CEPH HapMap individuals imputed all untyped SNPs in the case-
control cohort and tested them for association with CRC (Figure
S2). No additional SNP to the nine directly genotyped, provided
superior evidence for an association (P.1.16610
24) indicating our
selection of candidate SNPs based upon our LD criteria was
sufficient to identify a candidate variant. Analysis of the four most
significantly associated SNPs-rs16892766, Novel 28, rs16888589
and rs11986063 showed they are strongly correlated with one
another (i.e. pairwise r
2.0.75; Figure 1) and constitute a single risk
haplotype (P.8.61610
26). Collectively these data support the
hypothesisthat one ofthesefour variantsis likelytocontribute tothe
8q23 CRC association.
The promoter of the nearest protein-coding gene, EIF3H
(eukaryotic translation initiation factor 3, subunit H), maps 140 kb
telomeric to rs16892766; hence it is possible that rs16892766 or
another SNP in LD, affects an unknown element controlling
EIF3H expression. We excluded the possibility the 8q23
association signal is a consequence of a long-range LD with a
coding sequence change in EIF3H by resequencing the transcribed
regions and splice site boundaries of EIF3H. Only synonymous
SNPs were identified and none of these showed evidence of
correlation with rs16892766 (i.e. r
2,0.01, D’,0.01)
Sequence conservation in non-coding regions has been shown
to be a good predictor of cis-regulatory sequences [15]. Moreover,
it has been proposed that variation with evolutionary-conserved
regions is likely to be associated with phenotypic differences that
may contribute to expression of traits [15]. Cross-species sequence
comparison of the 22 kb interval revealed the presence of three
islands conserved between mammals annotated by rs16892766/
Novel 28, rs16888589 and rs11986063 (Figure 1). To further
examine the nature of the sequence within the 22 kB region we
implemented a number of computational methodologies. Using
ESPERR (evolutionary and sequence pattern extraction through
reduced representations), which searches for potential regulatory
sequences, all three islands are predicted to have regulatory
potential [16]. Using Enhancer Element Locator (EEL) software
[17] the strongest EEL-predicted regulatory element mapped to
island 1 as indicated in Figure 1.
To evaluate the potential enhancer activity of the three putative
regulatory regions, we cloned DNA fragments containing the three
conserved islands, incorporating the different alleles of
rs16892766-Novel 28, rs16888589 and rs11986063, into GFP or
LacZ reporter vectors designed to assay enhancer activity in
zebrafish, Xenopus and mice transgenic assays [10,18,19] or into
Luc2 reporter vectors to evaluate regulatory activity in human
CRC cell lines. Although no enhancer activity was detected for
any island in the different transgenic experiments, the cell culture
assays were compatible with island 1 and 3 acting as weak
enhancers. However, no allele-specific differences were observed
for the polymorphisms mapping to these islands (Figure S3). In
contrast, luciferase assays demonstrated that island 2 functions as a
repressor that was allele-specific (Figure 2). The ancestral A allele,
but not the risk G allele of rs16888589, significantly repressed luc2
reporter gene expression (P,0.01; Figure 2). These data are
consistent with island 2 in the CRC risk region natively
functioning as a repressor in allele-specific manner.
To investigate the effect of differential eIF3H expression on the
malignant phenotype of CRC; we selected LoVo, which has two
copies of EIF3H; and HT-29 which has high gene amplification
and expression of EIF3H (Figure S4). In the LoVo CRC line,
reduction of EIF3H levels by short interfering RNA (shRNA)
reduced cell proliferation (Figure 3). Conversely, EIF3H up-
regulation by transfection with lentivirus carrying an EIF3H
expression vector (pWP1-EIF3H) increased cellular proliferation
(Figure 3). In the CRC cell line HT-29 we were unable to achieve
complete knock-down of EIF3H, (Figure S4) most likely due to the
high basal level of expression present in this cell line. However,
anchorage-independent growth measured by soft agar assay was
associated with a 40% reduction in the number of colonies with
EIF3H knock-down (Figure 3). Collectively these findings provide
evidence that high eIF3h levels influence the establishment and
maintenance of CRC.
We have previously found no association between EIF3H
expression in EBV-transformed lymphoblastoid cells and 8q23 risk
genotype [5]. Likewise, we found no association between
rs16892766 and EIF3H mRNA expression in a series of colorectal
adenomas and carcinomas (Figure S5), or absence of copynumber
gain of 8q23 and EIF3H genotype.
Hypothesising that the 22 Kb region of 8q23 physically
interacts with the EIF3H we used chromosome conformation
capture (3C) to examine for interaction with the EIF3H promoter.
We interrogated a constant promoter fragment against a series of
fragments in LoVo and RKO CRC cell lines and a control
fibroblast cell line (Figure 5). In both CRC cell lines we observed
strong interaction between a fragment encompassing the promoter
and island 2 but not island 1 or island 3. Thus, the rs16888589 risk
region physically interacts with EIF3H. Intriguingly, a STAT
binding site (TTCCGGGAA) with differential allele affinity by
rs16888589 is predicted by TFsearch. Direct evidence for support
for allele specific functional consequences for rs16888589 were
provided by electrophoretic mobility shift assays (EMSA) showing
greater affinity for nuclear protein-DNA complex formation with
the risk allele (P=5.3610
24; Figure 5).
Author Summary
Common inherited variation on human chromosome 8q23
influences the risk of developing colorectal cancer (CRC).
To understand the basis of this association we have
compared the frequency of common genetic variants at
8q23 in ,2,000 CRC cases and ,2,000 healthy controls.
Functional analyses of variants strongly associated with
CRC risk showed that the single nucleotide polymorphism
rs16888589 underscores the 8q23.3 association. The region
of the genome harboring rs16888589 increases the
expression of the gene for eukaryotic translation initiation
factor 3, subunit H. We show that increased expression of
this gene increases CRC growth thereby providing a
biological mechanism for the 8q23.3 association. This
finding is of particular importance in elucidating the
etiological basis of CRC.
EIF3H and Risk of Colorectal Cancer
PLoS Genetics | www.plosgenetics.org 2 September 2010 | Volume 6 | Issue 9 | e1001126Figure 1. Association between SNPs and colorectal cancer risk at 8q23. (A) Single marker association statistics (-log10 P) of directly
genotyped SNPs (N, black) and imputed SNPs (N, blue). (B) Linkage disequilibrium (LD) statistics (r
2) of HapMap project data phase II. The darker the
shading indicates stronger LD between SNPs. (C) Details of the 22 Kb interval which was resequenced. SNPs displaying the strongest association
which were evaluated in biological assays are shown (N, green). Also shown is the sequence conservation across the region in mammals.
doi:10.1371/journal.pgen.1001126.g001
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rs6983267 is preferentially amplified during development of CRC
[20]. To examine whether a similar phenomenon exists for the
8q23 locus, we analyzed allelic imbalance at rs16892766. Analysis
of the 220 heterozygous tumors revealed copy number change in
20% (44/220) of the CRCs. rs6983267 is located 10.8 Mb distally
from rs16892766 and it is known that amplified regions in 8q can
be large [20]. Therefore, the G allele specific amplification of the
rs6983267 containing region could have an impact on the allelic
imbalance data on rs16892766. Thus, we restricted the allelic
imbalance analysis to the 133 rs6983267 homozygous tumors. Of
133 tumors, 27 showed allelic imbalance. In 11 tumors the risk
allele C was preferred whereas in 16 tumors the A allele was
favoured. No significant difference in the selection of the targeted
alleles was observed (P=0.44).
Discussion
In this work we have performed functional analysis and 3C
studies using CRC cell lines to maximize detection of a subtle
functional effect associated with rs16888589. Using these model
systems we were able to demonstrate that possession of the A allele
of rs16888589 may have repressor function on EIF3H. This does
not exclude the possibility of the regulatory region we identified
influences other genes through cis- and trans-effects. In addition,
we cannot rule out the possibility that other, rarer risk alleles
within the LD block may also contribute to the risk of CRC.
eIF3H is one of the 13 putative subunits of the eukaryotic
translation initiation factor 3 (EIF3). At the cellular level, EIF3H
overexpression increases proliferation, growth and survival. eIF3h
appears to function through translation, as the initial appearance of
overexpressed eIF3h in rapidly induced NIH-3T3 cells correlates
tightly with the stimulation of protein synthesis and the generation of
malignant phenotypes. Overexpression of EIF3H is seen in prostate,
breast, and liver cancer and overexpression of eIF3h malignantly
transformsimmortalNIH-3T3 cells[21–23]. Highlevel amplification
of the EIF3H has also been associated with advanced stage and poor
prognosis prostate cancer [24]. This is a general feature of eIF3h, as
high levels also affect translation, proliferation, and a number of
malignant phenotypes of CHO-K1 and HeLa cells and, most
significantly, of primary prostate cell line [23].
Reduction of eIF3h levels in breast and prostate cancer cell lines
by shRNA methods has previously been shown to reduce cell
proliferation and anchorage-independent growth in soft agar [22].
In our study we have now shown that that manipulating eIF3h
expression has a similar effect in CRC. These data provide
compelling evidence that high eIF3h levels directly stimulate
protein synthesis, resulting in the establishment and maintenance
of the malignant phenotype of CRC.
We found no association between rs16892766 and EIF3H
mRNA expression in a series of colorectal adenomas and
carcinomas. This is perhaps not entirely surprising given the
moderate effect of the variant on enhancer activity and the
relatively small numbers of samples analysed. Additionally, CRC
occurs late in life and it is likely that only a cumulative long-term
imbalance in EIF3H expression will influence CRC development.
Finally, expression differences may only be relevant to a specific
subpopulation of cells such as intestinal stem cells.
It has recently been suggested that analysis of transcript
abundance provides a means of establishing a relationship between
genotype an expression [25]. Hence analysis of the impact of
rs16888589 genotype and transcript abundance in different cell
lineages of colonic tissue at different stages of development and
may prove highly informative.
Overexpression of eIF3h has recently been shown to inhibit
Myc-dependent induction of apoptosis of primary prostate cells
and EIF3H and MYC and may cooperate in enhanced protein
translation either in a general way or for a specific subset of
mRNAs [23]. We have previously shown that the G allele of the
8q24 variant rs6983267 is preferentially amplified during
development of CRC [20]. In contrast there appears to be no
such selection for 8q23 alleles according to rs16892766 genotype.
In summary, we identified rs16888589 as a genetic risk variant
for CRC at 8q23.3 and in vitro experiments showed a functional
significance of this SNP. We propose that this risk allele of
rs16888589 acts as part of a cis-regulatory element for the EIF3H
promoter in CRC, which may mediate CRC risk through control
of EIF3H expression.
Materials and Methods
Ethics
Ethical committee approval for this study was obtained from
relevant study centres (UK, MREC02/0/97, Netherlands,
LUMC/CME P04.124 and the University of Helsinki).
Figure 2. Reporter gene activity for the island 2 construct
incorporating rs16888589. Luciferase reporter assays demonstrat-
ing repressor activity in LoVo and RKO CRC cell lines.
doi:10.1371/journal.pgen.1001126.g002
EIF3H and Risk of Colorectal Cancer
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DNA was extracted from 30 CEPH mother-father-child trios
(n=90; U.S. Utah residents with northern and western Europe
ancestry; Coriell cell depositories); Phase I and II HapMap
cohort.
Genotyping cohort
1,964 CRC cases (964 male; mean age at diagnosis 58 years;
SD, 8) ascertained through The National Study of Colorectal
Cancer Genetics (NSCCG) [26]. 2,081 healthy individuals (845
males; mean age 57 years; SD, 9) were recruited from NSCCG
(871), Genetic Lung Cancer Predisposition Study (1999–2004;
n=706) [27], and the Royal Marsden Hospital Trust/Institute of
Cancer Research Family History and DNA Registry (1999–2004;
n=504). All cases and controls were UK residents and had self-
reported European ancestry.
Resequencing
Sequence changes in 8q23 (117,690,773–117,712,909; UCSC
March 2006 assembly, NCBIbuild36.1) were identified by
sequencing. PCR and sequencing primers were designed using
Primer3 software (sequences available on request). Amplicons were
sequenced by ABI chemistry (BigDye v3.1; Applied Biosystems,
Foster City, US) and implemented on ABI 3730xl DNA analyzers
(Applied Biosystems, Foster City, US). Sequence reads were
analyzed using Mutation Surveyor software v3.10 (Softgenetics,
State College, US). For QC purposes all chromatograms were
visually inspected for base independently by two researchers.
Genotyping
DNA was extracted using conventional methodologies and
quantified using PicoGreen (Invitrogen, Renfrew, UK). Custom
genotyping was conducted using the Illumina Golden Gate system
Figure 3. Impact of differential EIF3H expression on growth of colorectal cancer cell lines. CRC cell line growth based on AlamarBlue
analysis. (A) HT-29 cells transduced with shRNA against EIF3H (shEIF3H) and control (shLUC). No effect on cell growth is seen. (B) LoVo cells
transduced with shRNA against EIF3H (shEIF3H) and control (shLUC). Suppression of EIF3H reduced the cell growth of LoVo. (C) LoVo cells
transduced with lentivirus carrying EIF3H expression vector (pWP1-EIF3H) and empty vector control (pWP1). The EIF3H overexpression increased
significantly the cell growth of LoVo. Mean values 6SEM are shown. (D) Impact of EIF3H expression on anchorage-independent growth of HT-29
colorectal cancer lines in soft agar assay. HT-29 cells transduced with pLL3.7 lentivirus carrying shRNA against EIF3H (shEIF3H) or against luciferase
(shLUC) were grown in soft agar followed by counting the colonies. Approximately 40% reduction in the number of colonies was found. Mean
values 6SEM are shown.
doi:10.1371/journal.pgen.1001126.g003
EIF3H and Risk of Colorectal Cancer
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Hertfordshire, UK). Assay details available on request. Genotyp-
ing quality control was tested using duplicate DNA samples. For
all SNPs, .99.9% concordant results were obtained.
Enhancer reporter assays in Xenopus, zebrafish and mice
Theallele-specificfragments(TableS3)ofeachIslandwerePCR-
amplified, sub-cloned into PCR8/GW/TOPO vector and verified
by PCR and direct sequencing. Gateway technology was then used
to transfer the DNA fragment to the corresponding destination
reporters. For zebrafish transgenesis, we transferred the DNA
fragments to the ZED destination vector [18]. This vector contains
the Xenopus Cardiac actin promoter driving DsRed as a positive
control for transgenesis. Zebrafish transgenic embryos were
generated as described [18]. Three or more independent stable
transgenic lines were generated for each construct. Xenopus laevis
transgenic embryos were generated using the I-SceI method [28]
with the reporter vector recently described [10]. For the generation
of transgenic mice, the genomic fragments were transferred into a
vector containing the human minimal beta-globin promoter, lacZ
and a SV40 polyadenylation signal [19]. Afterward, vectors were
linearized, the vector backbone removed and the construct
microinjected into one cell mouse embryos. F0 embryos of 11, 5–
13 dpc stages were harvested and stained for lacZ activity.
Luciferase assay
The allele-specific fragments of each Island were transferred
from PCR8/GW/TOPO vectors into pGL3 luc2 using the
gateway technology. pGL3 luc2 constructs were amplified in E.coli
followed by purification of plasmid DNA using Qiagen Endotoxin-
free Maxi-prep kits. LoVo (Human colon adenocarcinoma) and
RKO CRC cell lines (ECACC, Salisbury, UK) were grown in F12
(Ham’s) and McCoy’s 5a culture medium, respectively, supple-
mented with 10% FCS (37uC, 100% relative humidity, 5% CO2).
Cultured cells were seeded in 96-well tissue culture (Greiner)
plates, 2.7610
5 cells/well, in 200 ml of media and grown for
,24 hours until 80% confluent. Transient transfection was
carried out with Transfast transfection reagent (Promega, South-
ampton, UK) at a charge ratio of 1:1 of transfection reagent to
DNA in serum free medium. In each well, cells were transfected
with 150 ng of pGL3-construct DNA and 5 ng of the internal
control plasmid DNA (pRL-CMV, Promega) that encodes the
Renilla luciferase gene under the control of the CMV promoter. Six
replicates of cells, both LoVo and RKO were transfected by each
reporter construct. Each transfection experiment was repeated
twice. Transiently transfected cells were grown for 48 hours,
following which the luciferase assay was carried out using the
Dual-Glo luciferase assay system (Promega, Southampton, UK) as
per the manufactures instructions. Firefly luciferase (from the
pGL3 constructs) and renilla luciferase (from the pRL-CMV
internal control) were measured sequentially on a 96-well (Dynex
Inc, West Sussex, UK). The ratio of luminescence from the
experimental reporter to the luminescence from the control
reporter was calculated for each sample, defined as the relative
luciferase activity. Difference in relative activity of each experi-
ment was assessed using the Mann-Witney test.
Figure 4. Physical interaction of the CRC variant rs16888589 with EIF3H in CRC cell lines. (A) Physical map of the region interrogated by 3C.
The position of the constant fragment at the EIF3H promoter is shown in red. Genomic positions of target fragments (Table S3) are denoted by black
bars. (b) Graph showing the 3C interaction frequency containing the promoter with each target fragment in the LoVo and RKO CRC cell lines. Error bars
represent SEM. The results demonstrate increased interaction frequency in the cell lines between the EIF3H promoter and fragment I2 to which
rs16888589maps.TheY-axisreferstointeractionfrequency;RKOtotheright;LoVototheleft.Theassaywasperformedindependently fortwoandthree
times in RKO and LoVo colorectal cancer cell lines, respectively. Labels at each data point in the graph denote the name of each target fragment.
doi:10.1371/journal.pgen.1001126.g004
EIF3H and Risk of Colorectal Cancer
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3C assay was performed as previously described [29]. Adherent
cultured LoVo or RKO cells were processed to get a single cell
preparation. 10
7 cells were fixated with 2%PFA, lysated, and
nuclei were digested with HindIII (Roche, West Sussex, UK). DNA
was then ligated with T4 DNA ligase (Promega, Southhampton,
UK) in low concentration conditions to favour intramolecular
ligations. A set of locus specific primers (Table S3) were designed
close to the HindIII site. The primer near to EIF3H promoter
acting as the fixed primer, and different interactions were tested
using primers close to each island. Two negative control primers
were mapping 30 kb upstream and 20 kb downstream the three
islands (Figure 4; Table S3). PCR products were run in an agarose
gel and quantified using a Typhoon scanner. Product values were
normalised to a control composed of a BAC containing all test
fragments. We validated the ligation product of Island 2 (I2) with
the promoter fragment of EIF3H (promoter) by sequencing the
band from the agarose gel.
Electrophoretic mobility shift assay (EMSA)
Biotin end-labeled and unlabeled complementary oligonucleo-
tide probes (59-CCTTCTCTCTTCCCAGAACCCGGCTGTC-
CC-39–Biotin and 59- CCTTCTCTCTTCCCGGAACCCGGC-
TGTCCC-39) (Invitrogen, Renfrew, UK) were annealed to
generate double-stranded EMSA probes. Nuclear protein was
extracted from a lymphoblastoid cell line using NE-PER nuclear
and cytoplasmic extraction kits (Thermo Scientific, Loughbor-
ough, UK).
EMSA experiments were performed using the Lightshift
Chemiluminescent EMSA Kit (Pierce, Thermo Scientific, Lough-
borough, UK). Each 20 ul binding reaction contained 20 fmols of
biotin end-labeled target DNA, 106 binding buffer, 50 ng
Poly(dI.dC), 2.5% glycerol, 0.05% NP-40 and 5 ug of nuclear
protein extract. After a 20 minute incubation, reactions were
electrophoresed for 1 h at 100 V in a 6% polyacrylamide gel
(0.5% TBE buffer) and then electroblotted for 1 h at 30 V.
Chemiluminescent detection of biotin end-labeled DNA was
performed with a strepdavidin-horseradish peroxidase conjugate
captured onto X-ray film and developed according to the
manufacturers instructions. Omitting nuclear extract and addition
unlabelled probes (1000-fold excess) served as controls. Quantifi-
cation of intensity signals was performed using a BioRad CCD
Molecular Imager FLUOR-S (Biorad, Hemel Hampstead, UK).
EIF3H over-expression and knockdown in colorectal
cancer cell lines
Cell lines. HT-29 and LoVo CRC cell lines were obtained
from DSMZ (Braunschweig, Germany), and cultured under
recommended conditions.
Fluorescence in situ hybridization. Dual-color fluorescen-
ce in situ hybridization (FISH) with digoxigenin-dUTP (Roche
Diagnostics, West Sussex, UK) labeled PAC probe for EIF3H and
FITC-dUTP (NEN, Boston, MA, USA) labeled pericentromeric
probe for chromosome 8 (pJM128) were hybridized to interphase
nuclei of the cell lines as previously [30]. After stringent washes,
slides were stained with antidigoxigenin-rhodamine (Roche Dia-
gnostics) and counterstained with an antifade solution (Vectashi-
ed, Vector Laboratories, Burlingame, CA, USA) containing 4,6-
diamidino-2-phenylindole (DAPI). FISH signals were scored using
Olympus BX50 epifluorescence microscope (Olympus Inc, Tokyo,
Japan).
Lentivirus production and transductions. Lentiviral con-
structs were performed as previously described [21]. The sequences of
short hairpin RNAs (shRNAs) are given in Table S3. shRNA oligos
were obtained from Sigma-Proligo (The Woodlands, TX, USA) and
cloned into the lentiviral plasmid Lentilox3.7 (pLL3.7). cDNA clone of
EIF3S was obtained from Geneservice (Cambridge, UK) and cloned
into the lentiviral plasmid WPI. Both pLL3.7 and pWPI –plasmids
contain green fluorescence protein (GFP) as a reporter gene. Cells that
showed .90% transduction efficiency were used for the experiments.
To enhance the viral transduction, 8 mg/ml of polybrene (Sigma-
Aldrich, Milwaukee, WI, USA) was used in every transduction.
Quantitative real-time RT-PCR (q-RT-PCR). The expre-
ssion levels of EIF3H, and a housekeeping gene TATA-box
binding protein (TBP) were analyzed using previously described
methodology [21] Briefly, PCR reactions were performed using
the LightCycler apparatus (Roche Diagnostics, Mannheim,
Germany) with the LC Fast Start DNA SYBR Green I Kit
(Roche Diagnostics). Melting curve analysis and agarose gel runs
were performed to ensure the formation of specific PCR products.
Growth curves and soft agar assays. Growth curves and
soft agar assays were performed as previously described [21]. For
the growth curves cells transduced withlentiviruseswereplatedon a
24-well plate at 50 000 cells/ml density. Alamar Blue (Trek
Diagnostic Systems, Cleveland, OH, USA) was added to the wells
followed by fluorescence measurement after two hours of
incubation. Values were normalized against day 1. Each
experiment was performed in five replicates and repeated at least
twice. For soft agar assay, cells transduced with lentiviruses were
trypsinized and dilution of 5000 cells/well was mixed with 5%
agarose to form 0.35% upper layer. After two weeks, colonies were
photographed under UV-microscope and counted. All experiments
were conducted in triplicate and repeated at least twice.
Figure 5. Electro-mobility shift assay (EMSA) of rs16888589
showing differential binding of nuclear protein for A and G
alleles. Upper panel shows autoradiographs for binding of double
stranded A-allele and G-allele probes to lymphoblastoid nuclear
extracts; lower panel shows a 4-fold difference in binding between A
and G alleles.
doi:10.1371/journal.pgen.1001126.g005
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Allelic imbalance in the CRC tumors was scored as described in
Tuupanen et al. [20].
EIF3H expression and 8q23 copy number analysis
Snap-frozen rectal adenomas and carcinomas from patients
who had not received radiotherapy or adjuvant chemotherapy
were evaluated for EIF3H expression and 8q copy number. Frozen
tumors were macrodissected in a cryostat to achieve tumor
percentage assessed (50–80%), guided by H&E-sections. DNA was
isolated from tumors using the Genomic Wizard kit (Promega,
Madison, WI). Copy numbers were analyzed using GeneChip
Mapping 10 K 2.0 arrays (Affymetrix, Inc., Santa Clara, CA) as
described previously [31]. RNA was isolated from tumours using
the Qiagen RNeasy mini kit with DNaseI digestion (Qiagen
Sciences, Germantown, MD) and quality checked by lab-on-a-
chip (Agilent Technologies, Agilent Technologies, Palo Alto,
California). 2 ug RNA was hybridized to human 35 K oligo
microarrays from the CMF of the Netherlands Cancer Institute as
previously described [32] Comparison of the difference in
expression levels was assessed using the Mann-Whitney test.
Statistical and bioinformatics analysis
Statistical analyses were undertaken in Stata v10 (Station
College, US). Deviation of the genotype frequencies in the controls
from those expected under Hardy-Weinberg Equilibrium (HWE)
was assessed by x
2 test. Unconditional logistic regression was used
to calculate the per allele odds ratio (OR) of CRC and associated
95% confidence intervals (CIs) for each SNP. Haplotype analysis
was conducted in Haploview software (v4.0) and tested for
association via a likelihood ratio test. Linkage disequilibrium
metrics were calculated using Haploview software (v4.0).The
weight of evidence in favour of each associated SNP was
quantified by calculating Akaike weights [33]. Prediction of the
untyped SNPs in the case-control data were performed with
MACH1.0 on reference phased haplotypes from HapMap phase
II data (January 2007 on NCBI B35 assembly, dbSNP build 125)
and the SNP-discovery panel. Reference haplotypes were
constructed of all SNPs identified in the re-sequenced interval by
use of PHASE software [34].
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